Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Murri

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Annals of Internal Medicine|April 3, 2001
Adherence to protease inhibitorsR Murri, A Ammassari, A Antinori
AIDS (London, England)|August 1, 1996
Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxisA Antinori, R Murri, A Ammassari
Giornale Di Clinica Medica|May 1, 1989
[Naltrexone]F Schifano, R Murri, R Gava
JAMA|February 18, 1998
Defining and measuring quality of life in medicineR Murri, M Fantoni, A Antinori, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Reduction of bronchoscopy performances should be included in the advantages of highly active antiretroviral therapy (HAART)R Murri, A Cingolani, P Limongelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 1996
Fatal toxic epidermolysis induced by zidovudineR Murri, A Antinori, G Camilli, et al.
Lancet (London, England)|June 17, 1999
Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patientsR Murri, A Ammassari, A De Luca, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatmentA Ammassari, R Murri, A Cingolani, et al.
Lancet (London, England)|August 5, 1998
"Buffalo hump" in HIV-1 infectionA De Luca, R Murri, F Damiano, et al.
Lancet (London, England)|September 26, 1992
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumoniaA Antinori, R Murri, E Tamburrini, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Annals of Internal Medicine|April 3, 2001
Adherence to protease inhibitorsR Murri, A Ammassari, A Antinori
AIDS (London, England)|August 1, 1996
Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxisA Antinori, R Murri, A Ammassari
Giornale Di Clinica Medica|May 1, 1989
[Naltrexone]F Schifano, R Murri, R Gava
JAMA|February 18, 1998
Defining and measuring quality of life in medicineR Murri, M Fantoni, A Antinori, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Reduction of bronchoscopy performances should be included in the advantages of highly active antiretroviral therapy (HAART)R Murri, A Cingolani, P Limongelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 1996
Fatal toxic epidermolysis induced by zidovudineR Murri, A Antinori, G Camilli, et al.
Lancet (London, England)|June 17, 1999
Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patientsR Murri, A Ammassari, A De Luca, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatmentA Ammassari, R Murri, A Cingolani, et al.
Lancet (London, England)|August 5, 1998
"Buffalo hump" in HIV-1 infectionA De Luca, R Murri, F Damiano, et al.
Lancet (London, England)|September 26, 1992
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumoniaA Antinori, R Murri, E Tamburrini, et al.
Pageof 8